<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174628</url>
  </required_header>
  <id_info>
    <org_study_id>MOP-93627</org_study_id>
    <nct_id>NCT01174628</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism</brief_title>
  <acronym>ELOPE</acronym>
  <official_title>The ELOPE Study: Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term impact of Pulmonary Embolism (PE) on
      heart and lung function, quality of life, ability to work, symptoms of breathlessness and
      functional status of patients one year after their initial diagnosis and treatment for PE
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Limitation</measure>
    <time_frame>1 month</time_frame>
    <description>Exercise limitation will be assessed by VO2 max (% predicted) on cardiopulmonary exercise testing (CPET)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise Limitation</measure>
    <time_frame>12 months</time_frame>
    <description>Exercise limitation will be assessed by VO2 max (% predicted) on cardiopulmonary exercise testing (CPET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline</time_frame>
    <description>Quality of Life will be assessed using the SF-36v2 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 month</time_frame>
    <description>Quality of Life will be assessed using the SF-36v2 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of Life will be assessed using the SF-36v2 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life will be assessed using the SF-36v2 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of Life will be assessed using the SF-36v2 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Disease-Specific Measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Disease-Specific Measures</measure>
    <time_frame>1 month</time_frame>
    <description>Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Disease-Specific Measures</measure>
    <time_frame>3 months</time_frame>
    <description>Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Disease-Specific Measures</measure>
    <time_frame>6 months</time_frame>
    <description>Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Disease-Specific Measures</measure>
    <time_frame>12 months</time_frame>
    <description>Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pulmonary Embolism</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      platelet-poor plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in the Emergency Department, in-patient wards, out-patient clinics or
        anticoagulation clinics.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First episode of acute symptomatic PE that was objectively diagnosed* within last 10
             days

          2. Treated with anticoagulants

          3. â‰¥ 18 years old

               -  PE will be diagnosed if there is a high probability V/Q scan (as per PIOPED Study
                  criteria 66), an intraluminal filling defect in segmental or larger vessels on
                  CTPA or a constant intraluminal filling defect or abrupt cut-off of vessels
                  greater than 2.5 mm diameter on pulmonary angiography 8,10. Patients with
                  non-definitive test results (e.g. low or intermediate probability V/Q scan,
                  subsegmental PE on CTPA (~5% of PE patients 12) will not be included in order to
                  have a strictly defined population of patients with definite PE.

        Exclusion Criteria:

          1. Contraindication or unable to perform CPET or 6MWT (amputated or paralyzed limb(s),
             severe lower extremity arthritis, preexisting cardiopulmonary condition precluding
             exercise including unstable angina or myocardial infarction in last 6 weeks,
             uncontrolled hypertension, serious cardiac dysrhythmia on resting EKG [severe
             bradycardia or tachycardia, sick sinus syndrome or multifocal premature ventricular
             contractions] and syncope)

          2. Contraindication to CTPA (allergy to iodinated contrast, CrCl or eGFR &lt; 30 ml/min)

          3. Severe comorbidity (congestive heart failure [LVEF &lt; 35%], severe COPD or restrictive
             lung disease [FEV1&lt;50%, chronic need for oxygen therapy])

          4. Previous DVT (as ~40% of patients with proximal DVT have asymptomatic PE on lung
             imaging 67)

          5. Life expectancy &lt; 1 year (e.g. active or terminal cancer, end-stage cardiac or
             respiratory disease).

          6. Pregnancy or lactation

          7. Unable to read questionnaire in English or French

          8. Unable to return to study centre for required follow-up visits

          9. Unable or unwilling to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan R Kahn, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Mortimer B. Davis - Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Hirsch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Mortimer B. Davis - Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Granton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis - Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Susan Kahn</investigator_full_name>
    <investigator_title>M.D., M.Sc.</investigator_title>
  </responsible_party>
  <keyword>Exercise Tolerance</keyword>
  <keyword>Venous Thrombosis</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Quality of Life (QOL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

